about
Primary prevention of ischemic strokeGenome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.Gene by sex interaction for measures of obesity in the framingham heart study.Impact of gene variants on sex-specific regulation of human Scavenger receptor class B type 1 (SR-BI) expression in liver and association with lipid levels in a population-based study.Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemiaInterferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia.Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.Safety considerations with niacin therapy.Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).The editor's roundtable: Closing the clinical practice gap-using evidence-based treatments for managing lipids.Optimal management of lipids in diabetes and metabolic syndrome.Flushing and other dermatologic adverse events associated with extended-release niacin therapy.The use of niacin.Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes.Implanted estrogen pellets associated with hypertriglyceridemia, biliary dyskinesia and focal nodular hyperplasia of the liver: a case report.Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.Benefit versus risk in statin treatment.Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes.Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?Metabolic syndrome: evaluation of pathological and therapeutic outcomes.Metabolic syndrome: definition, pathophysiology, and mechanisms.Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses.Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.Niacin and heart disease prevention: Engraving its tombstone is a mistake.Low glycemic diet for weight loss in hypertriglyceridemic patients attending a lipid clinic.Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins.Statin safety: an assessment using an administrative claims database.Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemiaClinical assessment of atherosclerotic lesions: emerging from angiographic shadows
P50
Q22306369-9D69B2E1-FD1F-4778-936C-A09BCB42F31CQ30484496-9633A12E-1487-4C73-9A1C-FE486B752995Q30497912-AE1F7F7A-11FE-4420-A637-A1B52969A52EQ33525190-4C63E1DC-ECB9-498E-955C-874ED6E772D8Q33804581-7495A648-4326-4618-9480-1A80F4EAE70DQ34065725-DD53C16A-32B1-459A-AC58-5BFA59E4BD4BQ34647971-C96F379E-A054-4472-AAB4-093884A5A193Q34649206-C8BB08A7-88B9-45CF-B799-38F1226F06F0Q35841201-44971310-D902-46DC-8121-BE937CB030FCQ35890819-29142141-CC50-4CA0-B954-C9F06559A000Q36438054-5A1DCE83-ACDF-4D58-91B6-1AE1F2EEDA35Q36763069-891A5F92-1012-49DC-B056-0AE675B1FA2CQ37390626-4A67AFF9-6114-4663-9332-3F4DC6113C83Q37826492-7AD6B5DC-B68E-42A3-A7C6-A7ABD1B4E4D7Q37835402-8EDED6E3-2285-4A66-B299-003EF2F12DF9Q42688809-0E2056DC-8590-4C8F-950C-DB42BFA4FA67Q42752664-C93F2D60-2D69-4703-A3A7-2F716720E344Q42752756-A1128422-824D-418E-8EB4-AD7D41EA8CA2Q42752757-DECA3707-00AF-4F9A-8F8E-60B9EDF51408Q43119083-1A89D621-A453-408E-871F-3A893B3297D8Q43163847-A8099987-090B-45DE-891A-96A73833DC87Q43919588-561F5F52-D256-4683-9C27-747B0AFA83EEQ43923017-2F955430-44AA-4D59-ADB9-F2C203299E2EQ44157908-97C8ED86-56B6-4408-BE47-9D5834138D27Q44246233-0708232E-E097-4258-8512-0C4D218DD3CEQ44722490-1FFF3EE7-6407-4E21-AD74-DFDDC284C3D5Q45230909-09B5C67F-C3B1-4D28-A078-561592CED683Q45230910-F8766527-9CDC-495F-A622-933142826044Q46075606-E625CEA5-495D-49D5-94EA-4C3470CCE8D3Q46584752-E8576C27-55F3-45CB-A44C-B194E6128ACCQ46638920-7C5F8707-B608-4D39-8BA0-58B93010B6B7Q46931820-C9CCE2CF-10A4-4510-979A-FFA0CB767879Q46962236-B12F2174-2FFC-485E-B906-EBF4578323A9Q47402902-EE3D0174-4B38-4196-967E-81395E9A2D54Q47697188-E775E363-4EB1-4CD5-8575-B81E81DDF241Q48158517-4A9F19D3-E7DC-4EBB-B08E-A74AD64FB186Q51360170-866EC4A0-B3B8-4DE5-BDC6-B234E887053BQ53257757-27818463-201E-4DDE-941F-F7ECC8C0D963Q57131209-B80AB57C-1D87-46D6-AED5-51A84FD729D1Q74763856-A105E55D-4111-40EC-9A49-8198F0FBDFD5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
John Guyton
@ast
John Guyton
@en
John Guyton
@es
John Guyton
@nl
John Guyton
@sl
type
label
John Guyton
@ast
John Guyton
@en
John Guyton
@es
John Guyton
@nl
John Guyton
@sl
prefLabel
John Guyton
@ast
John Guyton
@en
John Guyton
@es
John Guyton
@nl
John Guyton
@sl
P106
P21
P31
P496
0000-0003-0224-7923